据香港联交所公告显示：
中国人工智能驱动医药纳米材料解决方案提供商--剂泰科技7666.HK全球发售2.01229亿股H股，发售价每股10.5港元，联席保荐人为富瑞、德意志银行以及中信证券，预计H股于5月13日开始在香港联交所买卖
中国生物技术公司英派药业7630.HK全球发售4,197.7万股H股，最高发售价每股21.75港元，联席保荐人为高盛以及中金公司，预计H股于5月13日开始在香港联交所买卖
(Reporting By Alison Lui)
((alison.lui@thomsonreuters.com; +852 3462 7749))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.